Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSI-RIS: Psilocybin and Risperidone in Treatment-Resistant Depression
NCT05710237Phase 2Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- Jul 2023
- Primary completion
- Apr 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in treatment-resistant depression (TRD), sponsored by Center for Addiction and Mental Health. Started Jul 2023; status: completed.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05710237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710237.